Abstract 11928: Galectin-3 is Associated With Adverse Cardiovascular Outcomes in Asymptomatic Individuals in the Atherosclerosis Risk In Communities (ARIC) Study
Introduction: Although galectin-3, an indicator of myocardial fibrosis, provides prognostic value in patients with established heart failure, its prognostic significance in a diverse, asymptomatic population is largely uncharacterized.
Objectives: We measured plasma galectin-3 in 9255 individuals free of cardiovascular disease at baseline (visit 4, 1996-1998) and evaluated prospective associations with incident coronary heart disease (CHD), heart failure (HF) hospitalization, ischemic stroke, or total mortality in the biracial Atherosclerosis Risk in Communities (ARIC) study.
Methods: Outcome incident rates were expressed as number of events per 1,000 patient years. Cox proportional hazard regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals for the association of quartiles of galectin-3 with each outcome. The models were adjusted for age, gender, race, total cholesterol, HDL cholesterol, SBP, anti-hypertensive medication, current smoking, diabetes status, estimated GFR, and log NT-proBNP. Interactions for race and sex were ascertained by adding a cross-product of race or sex and galectin-3 in the model.
Results: In the adjusted model, increasing quartiles of galectin-3 were independently associated with incident CHD, HF, and mortality (Table), with the highest HR for HF. The relationship was not significantly modified by gender or race, except for CHD where galectin-3 was associated with increased risk in whites but not blacks (interaction p=0.04). Galectin-3 quartiles were not associated with incident stroke in adjusted analysis.
Conclusion: In a large, bi-racial cohort of individuals free of CVD at baseline, galectin-3 is associated with increased risk of incident CHD, HF, and death. These data implicate myocardial fibrosis in the development of CVD in a community-based population of black and white adults.
Author Disclosures: D. Aguilar: Consultant/Advisory Board; Modest; Bristol-Myers Squibb. Other; Modest; Galactin Assays were supported by Abbott. V. Nambi: Consultant/Advisory Board; Significant; regional advisory board Sanofi Regeneron. Other; Significant; Provisional patent along with Roche, Baylor College of Medicine, University of North Carolina on use of biomarkers in prediction of heart failure, event adjudicator for a study sponsored by Siemens, s. W. Sun: None. E. Selvin: None. K. Matsushita: None. J.W. McEvoy: None. A.M. Shah: None. S.D. Solomon: Other; Significant; Member of the Executive Committee for TOPCAT. E. Boerwinkle: None. C.M. Ballantyne: Consultant/Advisory Board; Modest; Abbott Diagnostics, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Matinas BioPharma Inc, Novartis, Regeneron, Roche Diagnostic. Research Grant; Significant; NIH, AHA, ADA. Other Research Support; Significant; Abbott Diagnostic, Amarin, Amgen, Eli Lilly, Esperion, Ionis, Novartis, Pfizer, Regeneron, Roche Diagnostic, Sanofi-Synthelabo. Consultant/Advisory Board; Significant; Astra Zeneca, Merck, Pfizer, Sanofi-Synthelabo.
- © 2016 by American Heart Association, Inc.